Aeternum Health Announces Acquisition of Mining Interest in Nkamouna Project

What Happened
Aeternum Health, Inc. announced on Form 8-K that on September 21, 2026 it acquired all membership interests in American Renaissance Minerals LLC (ARM) from American Renaissance Resources LLC (ARR) under a Membership Interest Purchase Agreement. The deal is tied to ARM’s right to acquire the Nkamouna nickel‑cobalt mining project in Cameroon. In connection with the transaction, Aeternum agreed to issue up to 133,333,333 pre‑split shares of common stock or, if required by ownership limits in the agreement, pre‑funded warrants to purchase common stock — to be issued in stages upon achievement of project milestones. The company issued a press release about the transaction on September 25, 2026.

Key Details

• Transaction date: September 21, 2026 (Agreement) and press release dated September 25, 2026.
• Consideration: Up to 133,333,333 pre‑split shares or, if needed, pre‑funded warrants issued in stages tied to project milestones.
• Investor/observer rights: An Investor Rights Agreement gives ARR conditional board observer and registration rights only if ARR holds more than 9.9% of the Company’s “Registrable Securities”; ARR acknowledges it does not currently hold >9.9%.
• Rights termination: Observer rights and registration rights include specific termination conditions (e.g., 15 months if ownership drops below thresholds, or when Registrable Securities can be freely sold under Rule 144).

Why It Matters
This filing marks Aeternum’s entry into mining and production of critical minerals (nickel and cobalt), a strategic shift that could diversify the company’s business. The deal may be dilutive to existing shareholders because up to 133.3 million shares (or equivalent warrants) are conditioned to be issued as milestones are met. The agreement also gives ARR conditional governance-related rights (observer and registration rights) if its ownership crosses certain thresholds — a factor investors should monitor. The transaction is a material definitive agreement (Item 1.01) and the securities issuance is covered under the filing’s unregistered sales disclosure (Item 3.02).